ChromaTan Corporation
Edit

ChromaTan Corporation

http://www.chromatan.com/
Last activity: 31.05.2024
Active
Categories: AlternativeBioTechGoodsIndustryInformationManufacturingMedtechPlatformProductProduction
ChromaTan is an innovator in improving efficiencies and reducing costs of Biotechnology processes.
Mentions
39
Total raised: $2M
Email

Investors 6

Funding Rounds 1

DateSeriesAmountInvestors
31.05.2024Grant$2M-

Mentions in press and media 39

DateTitleDescription
31.05.2024ChromaTan Receives a $2M Phase IIB NIH GrantThe single-use, columnless, steady state continuous elution chromatography platform (Photo: Business Wire) ChromaTan, a Lower Gwynedd, PA-based bioprocessing and biotools biomanufacturing technology platform development company, received a ...
07.02.2023Across Q1 And Q2, Ben Franklin Tech Partners Is Investing Nearly $3M Into 12 Philly-Area StartupsIt’s a busy start to the year for Ben Franklin Technology Partners‘ (BFTP) Southeastern Pennsylvania branch. The state-backed firm recently announced it’s slated to make investments in seven local startup companies. The investments were dep...
06.02.2023Ben Franklin Technology Partners Invests $2M In 7 Philadelphia-Area Startups, Plans New $25M FundThe investments were made in two groups, with $1.3 million going to five tech startups and $700,000 doled out to two health care startups. The seven companies to receive investments from Ben Franklin Technology Partners are: The seven compa...
02.12.2021Revolutionizing the Manufacture of Medicine and MoreThe process is complex and it requires many steps to go from conception to market. And a new platform from ChromaTan, a startup with roots in Happy Valley, is poised to change a significant part of that process, streamlining chromatography ...
11.12.2020News brief­ing: CG On­col­o­gy nets $47M Se­ries D for blad­der can­cer stud­ies; Sin­gle-cell tran­scrip­tom­ic start­up rais­es $24M launch cashCG On­col­o­gy has some new cash to play with. The Irvine, CA-based biotech an­nounced Thurs­day it closed a $47 mil­lion Se­ries D round of pre­ferred stock fi­nanc­ing as the com­pa­ny con­tin­ues to ad­vance late-stage tri­als for its le...
02.12.2020News brief­ing: Ex­elix­is pays $20M to in-li­cense a pre­clin­i­cal ADC for the pipeline; An­oth­er pre­clin­i­cal biotech shoots for a big IPOEigh­teen months af­ter Ex­elix­is signed on to part­ner with Icon­ic Ther­a­peu­tics on an an­ti­body-drug con­ju­gate, more mon­ey is flow­ing. Ex­elix­is is pick­ing up its ex­clu­sive op­tion on the tis­sue fac­tor-tar­get­ing ADC now k...
12.11.2020News brief­ing: Small merg­er to ad­vance an­ti-ag­ing pro­gram; Sanger In­sti­tute spin­out nabs $50M from Se­ries CSmall-cap play­er Ak­ers Bio­sciences $AK­ER has en­gi­neered a re­verse merg­er with pri­vate com­pa­ny MyMD Phar­ma­ceu­ti­cals. The new com­bined biotech, which will re­tain the name MyMD, is ex­pect­ed to trade un­der the new tick­er $M...
06.11.2020News brief­ing: Chi­nese can­cer play­er gets $124M+ Se­ries C; IN8bio sets terms for $86M IPOA lit­tle less than two years af­ter a nine-fig­ure Se­ries B, Apol­lomics has re­turned to the ven­ture well. This time, the com­pa­ny has come out with even more mon­ey, pulling in $124.2 mil­lion for a Se­ries C round. The fund­ing will ...
19.10.2020News brief­ing: Ab­b­Vie and Roche's Ven­clex­ta scores an­oth­er FDA OK; Im­muno­Gen nabs Chi­na deal with $40M cashAb­b­Vie and Roche’s Ven­clex­ta has got­ten a new FDA thumbs up. The pair an­nounced Mon­day that reg­u­la­tors have ap­proved the drug in com­bi­na­tion with azac­i­ti­dine or low-dose cy­tara­bine for new­ly-di­ag­nosed acute myeloid leu...
14.04.2020Will, Italy’s Instagram-born news startup, raises €1.2 million and launches podcastWill, the first Italian Instagram-born community for generations interested in becoming more aware of the world around them, has closed a €1.2 million seed round. The lead investors are Davide Dattoli (Founder and CEO of Talent Garden), Fra...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In